M&A

M&A

Suven Pharma to acquire Sapala Organic for Rs.230-Cr

BSE Announcement   Economic Times  

Publicly listed Suven Pharmaceuticals is to acquire a controlling stake in Hyderabad-based contract research development organisation (CDMO) Sapala Organic for INR 229.5 crore, in an all cash deal. Suven will initially acquire a 67.5% equity stake of Sapala and the remaining stake after FY27. Sapala had reported a revenue of over INR 67 crore and adjusted EBITDA margins of around 45% for FY24.Sapala is an oligonucleotides focused CDMO player. Sapala was founded by P Yella Reddy who has extensive experience in nucleic acid chemistry and formerly worked as Director (R&D) with Aisin Cosmos R&D Co. Ltd (Toyota Group) in Japan and India for over 20 years.